Aducanumab: A Deep Dive into BIIB037 and its Impact The medication, previously known as BIIB037, constitutes a notable attempt to address early-stage Alzheimer's disease. Designed by Biogen, the treatment works by https://www.targetmol.com/compound/aducanumab